You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection

Choi, Jong Won MD*†; Park, Jun Yong MD*†‡; Ahn, Sang Hoon MD*†‡; Yoon, Ki Tae MD*†; Ko, Heung-kyu MD§; Lee, Do Yun MD§; Lee, Jong Tae MD§; Kim, Kyung Sik MD¶; Choi, Jin Sub MD¶; Han, Kwang-Hyub MD*†‡; Chon, Chae Yoon MD*†‡; Kim, Do Young MD*†‡

American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3181967da0
Original Article: Gastointestinal

Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center.

Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007.

Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE.

Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.

Author Information

From the *Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; †Liver Cirrhosis Clinical Research Center, Seoul, Korea; ‡Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; and Departments of §Interventional Radiology and ¶Surgery, Yonsei University College of Medicine, Seoul, Korea.

Supported by a grant (A050021) from the Korea Health 21 R and D project from the Ministry of Health and Welfare, Republic of Korea.

Reprints: Do Young Kim, MD, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, 120-752, South Korea. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.